Universite Claude Bernard – Lyon1

Centre National De La Recherche Scientifique

Universitè De Genève

Universitá Degli Studi Di Milano-bicocca

Institut National De La Sante Et De La Recherche Medicale

Sorbonne Université

Université De Poitiers

Peter Gregory Goekjian

Leonardo Scapozza

Luca Mologni

Marie-Thérèse Dimanche-Boitrel

Stéphane Bach

Claire Delehouze

William Bisson

Shaheen Ahmed

David Gueyrard

Arnaud Comte

Carlo Gambacorti-Passerini

Laurent Meijer

Philip Cohen

Amaury Patin

Yvette Mettey

Benoit Joseph

Florence Popowycz

Joseph D'Attoma

Sébastien Tardy

Alexandre Orsato

Joseph Benoit

Philippe Olivier Belmont

Johann Bosson

Carlo Gambacorti Passerini

Cedric Schneider

Pierre Garcia

The present invention relates to new N- and N-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. 

Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. 

Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I): as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

2-acylaminothiazoles for the treatment of cancer

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

Alpha-carbolines for the treatment of cancer

The invention relates to kinase inhibitors of the formula (I) in which &#x2014;Rto R&#x2550;H; ether or polyether, amino; NO; NH-carbamate; NH&#x2014;CO&#x2014;R, with R such as defined above; Nand derivatives thereof of the 1,2,3-triazole type; &#x2014;R=&#x2014;OH; halogen; &#x2014;OR with R such as defined above; OH-carbamate; OH-carbonate; NH, NH-carbamate; NH&#x2014;CO&#x2014;R, with R such as defined above; Nand derivatives thereof of the 1,2,3-triazole type; N(R,R); &#x2014;R'&#x2550;H or a C1-C12 alkyl, &#x2014;R&#x2550;H; R; (R or R&#x2032;)&#x2014;Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; &#x2014;Rand R&#x2550;H, C-Calkyl; &#x2014;Rand R&#x2550;H, R (or R&#x2032;) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.

Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological

The present invention relates to compounds of formula (I) 

Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl

Growing community of inventors

Lyons, France

Peter Gregory Goekjian